Chronic Lymphocytic Leukemia | Topics

 
SEQUOIA Trial Meets Primary PFS End Point Improvement With Frontline Zanubrutinib for CLL
August 02, 2021

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.

Julie Vose, MD, MBA, Discussed Toxicities Associated With Acalabrutinib or Ibrutinib for Chronic Lymphocytic Leukemia
July 27, 2021

CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.

Early Efficacy, Safety Noted With Lisaftoclax in First-in-Human CLL Trial
July 07, 2021

In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.